• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Oncolytics Biotech Inc. - Product Pipeline Review - H2 2011 Product Image

Oncolytics Biotech Inc. - Product Pipeline Review - H2 2011

  • ID: 1964306
  • October 2011
  • 124 pages
  • Global Markets Direct

Oncolytics Biotech Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Oncolytics Biotech Inc. - Product Pipeline Review - H2 2011” provides data on the Oncolytics Biotech Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oncolytics Biotech Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Oncolytics Biotech Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oncolytics Biotech Inc. - Brief Oncolytics Biotech Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncolytics Biotech Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules READ MORE >



List of Tables
List of Figures
Oncolytics Biotech Inc. Snapshot
Oncolytics Biotech Inc. Overview
Key Information
Key Facts
Oncolytics Biotech Inc. – Research and Development Overview
Key Therapeutic Areas
Oncolytics Biotech Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Oncolytics Biotech Inc. – Pipeline Products Glance
Oncolytics Biotech Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Oncolytics Biotech Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oncolytics Biotech Inc. – Drug Profiles
Reolsyin + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Reolysin
Product Description
Mechanism of Action
R&D Progress
Reolysin + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Reolysin + FOLFIRI
Product Description
Mechanism of Action
R&D Progress
Reolysin + Gemzar
Product Description
Mechanism of Action
R&D Progress
Reolysin + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Oncolytics Biotech Inc. – Pipeline Analysis
Oncolytics Biotech Inc. – Pipeline Products by Therapeutic Class
Oncolytics Biotech Inc. - Pipeline Products By Target
Oncolytics Biotech Inc. – Pipeline Products by Route of Administration
Oncolytics Biotech Inc. – Pipeline Products by Molecule Type
Oncolytics Biotech Inc. – Recent Pipeline Updates
Oncolytics Biotech Inc. – Company Statement
Oncolytics Biotech Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 31, 2003: Oncolytics Biotech Inc Reports Presentation of Results From Interim Assessment of T2 Prostate Cancer Trial For REO 002
Mar 31, 2003: Oncolytics Biotech Inc Reports Presentation of Results From Interim Assessment of T2 Prostate Cancer Trial For REO 002
Mar 30, 2010: Oncolytics Announces Start Of Enrollment In US Phase II SCC Lung Cancer Trial
Mar 30, 2010: Oncolytics Starts Enrollment In US Phase II SCC Lung Cancer Trial
Nov 29, 2010: Oncolytics Announces Publication Of Phase I Clinical Trial Results Examining Combination Of REOLYSIN And Docetaxel In Clinical Cancer Research
May 29, 2007: Oncolytics Biotech Inc. Starts Patient Enrolment In U.K. Combination Reolysin/Paclitaxel And Carboplatin Trial
Sep 28, 2005: Oncolytics Biotech Inc. Begins Patient Enrolment In U.S. Systemic Delivery Clinical Trial For REO 004
Feb 28, 2005: Oncolytics Biotech Receives FDA Clearance To Initiate Phase I/II Recurrent Malignant Gliomas Clinical Trial For The Trial REO 007
Feb 27, 2004: Oncolytics Biotech Provides Final Update On T2 Prostate Cancer Study For REO 002
Feb 27, 2004: Oncolytics Biotech Receives Approval To Initiate UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN For Trial REO 005
Jan 27, 2009: Oncolytics Biotech Inc. Announces Start Of Patient Enrolment In Translational Clinical Trial Investigating REOLYSIN In Patients With Metastatic Colorectal Cancer For The Trial REO 013
May 26, 2010: Oncolytics Biotech Initiates Enrolment In US Phase II Pancreatic Cancer Clinical Trial
May 25, 2010: Oncolytics Biotech Opens Enrollment In Phase III Trial For REOLYSIN In Head And Neck Cancers
Mar 25, 2009: Oncolytics Biotech Inc. Completes Enrolment in Combination REOLYSIN/Gemcitabine Trial For The Trial REO 009
Oct 24, 2007: Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN and Radiation Clinical Trial For The Trial REO 006
Sep 24, 2009: Oncolytics Biotech Inc. Announces Reovirus And Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
Sep 24, 2009: Oncolytics Biotech Inc. Announces Reovirus And Cisplatin Research Supports U.S. Phase II Metastatic Melanoma Trial
Sep 24, 2009: Oncolytics Biotech Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial For The Trial REO 020
Sep 24, 2009: Oncolytics Biotech Inc. Announces Start Of Enrolment In U.S. Phase II Melanoma Cancer Clinical Trial
Mar 24, 2011: Oncolytics Completes Patient Enrollment In US Phase II Clinical Trial Investigating REOLYSIN In Combination With Paclitaxel And Carboplatin In Head And Neck Cancers
Dec 23, 2002: Oncolytics Biotech Announces Positive Interim Safety Results from REOLYSIN Phase I Malignant Glioma Study
Oct 23, 2008: Oncolytics Biotech Inc. Collaborators To Present Combination REOLYSIN And Paclitaxel/Carboplatin Results At iSBTc Annual Meeting
Oct 23, 2007: Oncolytics Biotech Inc. Announces Approval For U.K. Clinical Trial Investigating REOLYSIN In Combination With Cyclophosphamide
Oct 23, 2007: Oncolytics Biotech Inc. Announces Approval For U.K. Clinical Trial Investigating REOLYSIN In Combination With Cyclophosphamide For The Trial REO 012
Aug 23, 2006: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase I Systemic Administration Clinical Trial For REO 004
Aug 23, 2006: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase I Systemic Administration Clinical Trial For Trial REO 004
Apr 23, 2010: Oncolytics Completes Patient Enrollment In Phase I Portion Of US Phase I/II Recurrent Malignant Gliomas Clinical Trial With REOLYSIN
Feb 23, 2011: Oncolytics Biotech Announces Completion Of Enrollment In Translational Clinical Trial Investigating REOLYSIN In Patients With Metastatic Colorectal Cancer
Dec 22, 2006: Oncolytics Biotech Inc. Announces Approval For U.K. Clinical Trial Investigating REOLYSIN In Combination With Paclitaxel And Carboplatin
Dec 21, 2007: Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN/Radiation Clinical Trial For The Trial REO 006
May 21, 2010: Oncolytics Biotech Announces Reovirus Research To Be Presented At ASCO Annual Meeting
Mar 21, 2002: Oncolytics Biotech Inc Announces REOLYSIN Phase I Clinical Trial Results
Jun 20, 2008: Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN In Combination With Paclitaxel And Carboplatin For The Trial REO 015
Jun 20, 2008: Oncolytics Biotech Inc. Announces U.S. Phase II Clinical Trial Investigating Reolysin In Combination With Paclitaxel And Carboplatin
Apr 20, 2011: Oncolytics Biotech Announces Positive Data From Translational Clinical Trial Investigating REOLYSIN In Patients With Metastatic Colorectal Cancer
Mar 20, 2009: Oncolytics Biotech (ONCY) Collaborators Update Combination REOLYSIN and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Mar 20, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Head and Neck Results In Phase I/II Combination REOLYSIN And Paclitaxel/Carboplatin Trial
Mar 20, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Head And Neck Results In Phase I/II Combination REOLYSIN And Paclitaxel/Carboplatin Trial For The Trial REO 011
Jul 19, 2010: Oncolytics Receives No Objection Letter From Health Canada To Conduct Phase III Trial Of REOLYSIN In Head And Neck Cancers
May 19, 2010: Oncolytics Initiates Phase I Colorectal Cancer Study Of REOLYSIN In Combination With FOLFIRI
Dec 18, 2008: Oncolytics Biotech Inc. Completes Patient Enrolment In Two U.K. REOLYSIN Combination Therapy Clinical Trials For The Trial REO 008
Dec 18, 2008: Oncolytics Biotech Inc. Completes Patient Enrolment In Two U.K. REOLYSIN Combination Therapy Clinical Trials For The Trial REO 010
Nov 18, 2010: Oncolytics Announces Phase I Study In Pediatric Patients With Relapsed Or Refractory Solid Tumors To Be Conducted By Children's Oncology Group
May 18, 2010: Oncolytics Announces Publication Of Phase I Clinical Trial Results In Clinical Cancer Research
Feb 18, 2005: Oncolytics Biotech Inc. Announces Approval For U.K. Clinical Trial Investigating REOLYSIN In Combination With Radiation Therapy For The Trial REO 006
Jan 18, 2011: Oncolytics Biotech Announces 2-Arm, Randomized Phase II Pancreatic Cancer Study
Jan 17, 2006: Oncolytics Biotech Inc. Announces Conclusion of Patient Follow Up In Canadian Phase I Recurrent Malignant Glioma Clinical Trial
Apr 16, 2002: Oncolytics Biotech Inc Starts First Patient Treatment In Prostate Cancer Trial For REOLYSIN
Feb 16, 2011: Oncolytics Starts Enrollment In Randomized Phase II Pancreatic Cancer Study
Feb 16, 2010: Oncolytics Biotech Receives Approval From The U.K. MHRA To Conduct Phase II Trial For REOLYSIN In Head And Neck Cancers
Feb 16, 2010: Oncolytics Receives Approval From UK MHRA To Conduct Phase III Trial For REOLYSIN In Head And Neck Cancers
Nov 14, 2008: Oncolytics Biotech Inc. Collaborators Presents Reolysin Research at CTOS Annual Meeting
Feb 14, 2011: Oncolytics Biotech Meets Primary Endpoint For First Part of US Phase II Pancreatic Cancer Trial
Dec 13, 2001: Oncolytics Biotech Inc. Announces REOLYSIN Phase I Clinical Trial Interim Results
Dec 13, 2001: Oncolytics Biotech Inc. Announces REOLYSIN Phase I Clinical Trial Interim Results
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
Mar 12, 2009: Oncolytics Biotech Inc. Announces Start Of Enrolment In U.S. Phase II Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS Or EGFR-Activated Tumours
Oct 11, 2001: Oncolytics Biotech Announces Approval To Proceed with Clinical Trial To Evaluate REOLYSIN For The Treatment Of Prostate Cancer
Apr 11, 2002: Oncolytics Biotech Inc. Receives Approval To Initiate Canadian Phase I/II Brain Cancer Trial For REO 003
May 10, 2011: Oncolytics Biotech Announces Phase I Multiple Myeloma Cancer Study
Jan 10, 2011: Oncolytics Announces Opening Of Enrollment In US Phase I Colorectal Cancer Study Of REOLYSIN In Combination With FOLFIRI
Nov 09, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting.
Nov 09, 2006: Oncolytics Biotech Inc.’s Research Collaborators Present REOLYSIN Phase I UK Systemic Administration Clinical Trial Results For The Trial REO 005
May 09, 2008: Oncolytics Biotech Inc. Starts Patient Enrolment In U.K. Combination Reolysin/Cyclophosphamide Trial
Apr 09, 2008: Oncolytics Biotech Inc. Reports Positive Interim Results Of U.K. Combination Reolysin And Carboplatin/Paclitaxel Trial
Sep 08, 2008: Oncolytics Biotech Inc. Starts Patient Enrolment In U.S. Phase II Clinical Trial Investigating Reolysin In Combination With Paclitaxel And Carboplatin
Apr 08, 2010: Oncolytics Announces Publication Of Preclinical Research On Combination Of Antiangiogenic Cancer Therapy With Oncolytic Virotherapy
Mar 08, 2002: Oncolytics Biotech Inc. Files Application With U.S. FDA To Initiate Phase I/II Recurrent Glioma Trial For REO 003
Jun 07, 2010: Oncolytics Collaborators Present Positive Updated UK Phase I/II Trial Results In Advanced Solid Cancers At ASCO Annual Meeting
Apr 07, 2009: Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial For The Trial REO 008
Apr 07, 2005: Oncolytics Biotech Inc. Receives FDA Clearance To Initiate Phase I Systemic Delivery Clinical Trial For REO 004
Apr 07, 2005: Oncolytics Biotech Inc. Receives FDA Clearance To Initiate Phase I Systemic Delivery Clinical Trial For REO 004
Nov 06, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting For The Trial REO 014
Jul 06, 2011: Oncolytics Biotech Collaborators Present Positive REOLYSIN Clinical Trial Results At 14th World Conference On Lung Cancer
Jun 05, 2007: Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
Jun 05, 2007: Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
Jun 05, 2006: Oncolytics Biotech Inc. Completes Patient Enrolment in UK Phase I Systemic Administration Clinical Trial For The Trial REO 005
Jun 05, 2006: Oncolytics Biotech Inc.’s Research Collaborators Present Positive REOLYSIN Clinical Trial Data at ASCO Conference
Jun 05, 2006: Oncolytics Biotech Inc.’s Research Collaborators Present Positive REOLYSIN Clinical Trial Data at ASCO Conference For The Trial REO 005
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results At iSBTc Annual Meeting
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results at iSBTc Annual Meeting For The Trial REO 010
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN And Paclitaxel/Carboplatin Results At iSBTc Annual Meeting
Jul 03, 2002: Oncolytics Commences Phase I/II Brain Cancer Trial - First Trial Patient Receives REOLYSIN
Jan 03, 2007: Oncolytics Biotech Inc. Announces Approval For U.K. Clinical Trial Investigating REOLYSIN In Combination With Docetaxel For The Trial REO 010
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
Sep 02, 2008: Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS Or EGFR-Activated Tumours For The Trial REO 016
Sep 02, 2008: Oncolytics Biotech Inc. Announces U.S. Phase II Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS or EGFR-Activated Tumours
Aug 02, 2011: Oncolytics Biotech Announces Publication Of Preclinical Research On Synergistic Combination Of Chemotherapy With Oncolytic Virotherapy
Jul 02, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.K. Combination REOLYSIN And Paclitaxel/Carboplatin Head And Neck Cancer Trial
Jul 02, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.K. Combination REOLYSIN And Paclitaxel/Carboplatin Head and Neck Cancer Trial For The Trial REO 011
Dec 01, 2010: Oncolytics Announces Start Of Enrollment In Randomized Phase II Ovarian Cancer Study
Jun 01, 2010: Oncolytics Receives Approval From Belgium FAMHP To Conduct Phase III Trial For REOLYSIN In Head And Neck Cancers
Jun 01, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At ASCO Annual Meeting For The Trial REO 009
Jun 01, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting For REO 004
Jun 01, 2009: Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting For The Trial REO 004
Financial Deals Landscape
Oncolytics Biotech Inc., Deals Summary
Oncolytics Biotech Inc., Pharmaceuticals & Healthcare, Deal Details
Equity Offering
Oncolytics Biotech Raises $7.87 Million Upon Exercise Of Warrants
Oncolytics Biotech Raises $6.8 Million Upon Exercise Of Warrants
Oncolytics Biotech Completes Private Placement Of $28 Million
Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option
Oncolytics Biotech Completes Public Offering Of $6 Million
Oncolytics Biotech Completes Public Offering Of $3 Million
Oncolytics Biotech Completes Public Offering Of $12 Million
Oncolytics Biotech Completes Private Placement Of $16 Million
Oncolytics Biotech Raises $2.6 Million Upon Exercise Of Warrants
Oncolytics Biotech Raises $4.1 Million Upon Exercise Of Warrants
Oncolytics Biotech Completes Private Placement Of $8.28 Million
Oncolytics Biotech Completes Private Placement Of $5 Million
Acquisition
Oncolytics Acquires 10% Stake In British Canadian Biosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Oncolytics Biotech Inc. – Pipeline by Therapy Area and Indication, H2 2011
Oncolytics Biotech Inc. – Pipeline by Stage of Development, H2 2011
Oncolytics Biotech Inc. – Monotherapy Products in Pipeline, H2 2011
Oncolytics Biotech Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Oncolytics Biotech Inc. - Phase II, H2 2011
Oncolytics Biotech Inc. - Phase I, H2 2011
Oncolytics Biotech Inc. - Pipeline By Therapeutic Class, H2 2011
Oncolytics Biotech Inc. - Pipeline By Target, H2 2011
Oncolytics Biotech Inc. – Pipeline By Route of Administration, H2 2011
Oncolytics Biotech Inc. – Pipeline By Molecule Type, H2 2011
Oncolytics Biotech Inc. – Recent Pipeline Updates, H2 2011
Oncolytics Biotech Inc., Other Locations
Oncolytics Biotech Inc., Subsidiaries
Oncolytics Biotech Inc., Deals Summary
Oncolytics Biotech Raises $7.87 Million Upon Exercise Of Warrants
Oncolytics Biotech Raises $6.8 Million Upon Exercise Of Warrants
Oncolytics Biotech Completes Private Placement Of $28 Million
Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option
Oncolytics Biotech Completes Public Offering Of $6 Million
Oncolytics Biotech Completes Public Offering Of $3 Million
Oncolytics Biotech Completes Public Offering Of $12 Million
Oncolytics Biotech Completes Private Placement Of $16 Million
Oncolytics Biotech Raises $2.6 Million Upon Exercise Of Warrants
Oncolytics Biotech Raises $4.1 Million Upon Exercise Of Warrants
Oncolytics Biotech Completes Private Placement Of $8.28 Million
Oncolytics Biotech Completes Private Placement Of $5 Million
Oncolytics Acquires 10% Stake In British Canadian Biosciences

List of Figures
Oncolytics Biotech Inc. – Pipeline by Therapy Area and Indication, H2 2011
Oncolytics Biotech Inc. – Pipeline by Stage of Development, H2 2011
Oncolytics Biotech Inc. – Monotherapy Products in Pipeline, H2 2011
Oncolytics Biotech Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Oncolytics Biotech Inc. – Pipeline By Therapeutic Class, H2 2011
Oncolytics Biotech Inc. - Pipeline By Target, H2 2011
Oncolytics Biotech Inc. – Pipeline By Route of Administration, H2 2011
Oncolytics Biotech Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos